Patisiran vs Vutrisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Polyneuropathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline

Patisiran · ONPATTRO

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with PolyneuropathyRNAi
Reliable signal

NCT01960348 · Phase 3 · completed

In this randomized, double-blind, placebo-controlled phase 3 trial, 225 participants received patisiran (148) or placebo (77). The hard clinical primary endpoint, change in mNIS+7 at 18 months, favored patisiran and was statistically significant: -6.03 versus 27.96 points, a between-group difference of -33.99 (p<0.0000001).

Reported efficacy

Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) (met)

Result source: NCT01960348

Vutrisiran · AMVUTTRA

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with PolyneuropathyRNAi
Partial signal

NCT03759379 · Phase 3 · completed

This was a randomized but open-label study, and its primary comparison used 122 vutrisiran-treated participants versus 77 participants from an external APOLLO placebo group rather than a concurrent blinded placebo arm. The clinical primary endpoint, change in mNIS+7 at Month 9, favored vutrisiran and was statistically significant, but the lack of blinding and use of an external comparator limit the strength of the evidence.

Reported efficacy

Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) (met)

Result source: NCT03759379

Results for Transthyretin Amyloidosis with Polyneuropathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Patisiran
Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) NCT01960348 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Vutrisiran
Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) NCT03759379 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Patisiran's landscape · Vutrisiran's landscape